A short clip, but a meaningful one: the promise is not to manufacture stem cells, but to trigger partial, controlled reprogramming inside the eye. The OSK approach uses three Yamanaka genes in an attempt to restore visual function, with one central constraint: rejuvenate cells without making them lose their identity.
What the clip highlights
- A drug candidate coming from the speaker’s lab.
- Years of work credited to his student Wanlu.
- A three-gene Yamanaka subset known as OSK.
- Explicit caution around cancer risk and loss of cell identity.
- An upcoming test in a patient’s eye.
- Prior results described as strong in mice and monkeys.
Why this signal matters
Partial cellular reprogramming is one of the major bets in longevity medicine. Here, the practical target is specific: vision. The scientific challenge is to apply rejuvenation without crossing the dangerous line into stem-cell conversion. The next milestone to watch is the move from preclinical success to a patient test.
Key takeaway
OSK is presented as a compromise: enough reprogramming to aim for functional rejuvenation, not enough to erase cellular identity. If that logic holds in the human eye, it could become an important signal for targeted regenerative therapies.
Source
- Chaîne: Peter H. Diamandis
- Vidéo source: https://www.youtube.com/shorts/6dup1kJ0_Mg
No comments yet